Biosimilars Pathway In WHO Draft Guidance Drops Dual-track Approach
A World Health Organization working group dropped the less rigorous of two approaches for regulating biosimilars from its latest draft guidelines, a positive step, according to generic drug maker Sandoz
You may also be interested in...
Expert committee urges countries to move cautiously in licensing biosimilars, even though some products can require reduced data packages.
Clinical trials would be required for most biosimilars under two approval scenarios that are being developed by the World Health Organization
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011